Sign inCreate account

Report workspace

Add to folder
NCT00775931COMPLETEDanonymous

Allogeneic Hematopoietic Stem Cell Transplantation For Severe Osteopetrosis

Sponsor

Source record

Masonic Cancer Center, University of Minnesota

Phase

Source record

PHASE2

Modality

AI-normalized

cell therapy

Target

AI-normalized

umbilical cord blood transplantation, Campath-1H, Total Lymphoid Irradiation, Cyclophosphamide, Busulfan, Fludarabine monophosphate, marrow graft transplantation

Indication / condition

AI-normalized

Severe Osteopetrosis

Intervention

Source record

umbilical cord blood transplantation, Campath-1H, Total Lymphoid Irradiation, Cyclophosphamide, Busulfan, Fludarabine monophosphate, marrow graft transplantation

Related intelligence directories

Indication directory: Severe OsteopetrosisModality directory: cell therapyTarget directory: umbilical cord blood transplantation

Source & freshness

Source record

NCT ID

NCT00775931

Original source

ClinicalTrials.gov

Source last updated

Jul 31, 2019

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00775931

Title

Allogeneic Hematopoietic Stem Cell Transplantation For Severe Osteopetrosis

Sponsor

Masonic Cancer Center, University of Minnesota

Status

COMPLETED

Phase

PHASE2

Condition raw

Severe Osteopetrosis

Condition normalized

Severe Osteopetrosis

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

umbilical cord blood transplantation, Campath-1H, Total Lymphoid Irradiation, Cyclophosphamide, Busulfan, Fludarabine monophosphate, marrow graft transplantation

Target normalized

umbilical cord blood transplantation, Campath-1H, Total Lymphoid Irradiation, Cyclophosphamide, Busulfan, Fludarabine monophosphate, marrow graft transplantation

Interventions

umbilical cord blood transplantation, Campath-1H, Total Lymphoid Irradiation, Cyclophosphamide, Busulfan, Fludarabine monophosphate, marrow graft transplantation

Public preview

Source record

The purpose of this research is to explore what we believe may be a safer and more effective means of performing stem cell transplantation in patients with Osteopetrosis, using chemotherapy and radiation designed to bring about engraftment and lessen transplant mortality. Prior multi-institutional data in past studies found that approximately 30% of Osteopetrosis patients do not engraft. Therefore, in this study, we utilize a reduced intensity design of pre-transplant drugs to try to make transplants safer for this disease, as well as to provide a second infusion of stem cells in patients with matched related or unrelated donors.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Allogeneic Hematopoietic Stem Cell Transplantation For Severe Osteopetrosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT00775931

Status

COMPLETED

Phase

PHASE2

Sponsor

Masonic Cancer Center, University of Minnesota

Executive brief

Investment-Ready Snapshot

The purpose of this research is to explore what we believe may be a safer and more effective means of performing stem cell transplantation in patients with Osteopetrosis, using chemotherapy and radiation designed to bring about engraftment and lessen transplant mortality. Prior multi-institutional data in past studies found that approximately 30% of Osteopetrosis patients do not engraft. Therefore, in this study, we utilize a reduced intensity design of pre-transplant drugs to try to make transplants safer for this disease, as well as to provide a second infusion of stem cells in patients with matched related or unrelated donors.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJul 31, 2019
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00775931

Indication

Severe Osteopetrosis

Modality

cell therapy

Target

umbilical cord blood transplantation, Campath-1H, Total Lymphoid Irradiation, Cyclophosphamide, Busulfan, Fludarabine monophosphate, marrow graft transplantation

Intervention

umbilical cord blood transplantation, Campath-1H, Total Lymphoid Irradiation, Cyclophosphamide, Busulfan, Fludarabine monophosphate, marrow graft transplantation

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.